Cargando…
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
Autores principales: | Aqeel, Faten, Zonozi, Reza, Jeyabalan, Anushya, Sauvage, Gabriel, Niles, John L, Geetha, Duvuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462954/ https://www.ncbi.nlm.nih.gov/pubmed/37640515 http://dx.doi.org/10.1136/rmdopen-2023-003435 |
Ejemplares similares
-
Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022) -
Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023) -
Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023) -
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020) -
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)